Human Genetic Signatures and Unest announced in 2003 that a license agreement has been concluded for the use of intercalating nucleic acids (INAs) in the field of human epigenetics
INAs are a new generation of modified nucleic acids with unique attributes compared to all existing modified nucleic acids.
They exhibit exceptional promise in the clinical, diagnostic and therapeutic arenas of human diseases.
This juxtapositioning of the complementary technological developments and commercial avenues of Human Genetic Signatures and Unest, provides exceptional synergies between the technology and IP platforms of the two companies, and generates powerful traction in the clinical and therapeutic areas of personalized medicine, in important common human diseases, and in world wide studies of the genetic structures of human populations.
